

The Cost of 340B to Indiana

In 2025, workers and employers lost \$307 million in negotiated rebates to 340B

Despite advocates' claims that the 340B program is free, it raises costs for patients, employers, state and local governments, Medicare, and managed Medicaid. One way it increases costs is by displacing the negotiated rebates that are used to lower net drug prices. Research by IQVIA shows that workers and employers lost \$14.5 billion in rebates nationally in 2025 due to 340B.¹ The cost to Indiana workers and employers in 2025 was \$307 million.

Cost of 340B to Indiana workers and employers

PER BENEFICIARY	PLAN TYPE	TOTAL COST
\$83	Private sector employees ²	\$270M
	Government employees ³	\$37M
	Total	\$307M

340B also displaces rebates in managed Medicaid, which cost the state of Indiana \$39M in 2025.

Cost of 340B to Indiana managed medicaid

PER BENEFICIARY	STATE'S TOTAL COST
\$36	\$39M

The cost of 340B to Indiana has increased substantially in recent years due to program growth. From 2023 to 2025, the number of healthcare providers prescribing 340B drugs, the number of 340B facilities, and the value of 340B drug purchases all increased.

340B growth in Indiana: 2023 to 2025

340B PRESCRIBERS		340B FACILITIES ⁴		340B DRUG PURCHASES ⁵	
#	GROWTH	#	GROWTH	#	GROWTH
263,810	+16%	3,270	+9%	\$4.0 billion	+10%

340B utilization varies somewhat across Indiana and neighboring states, underscoring that the program's financial burden is not borne uniformly.

Indiana vs. neighbors

STATE	340B UTILIZATION ⁶	COST PER BENEFICIARY
IN	14%	\$83
MI	21%	\$121
OH	16%	\$90
IL	12%	\$71
Total U.S.	14%	\$81

1. The cost of 340B to states. IQVIA. 2026 (to appear).
2. Includes employer-sponsored plans and ACA health plans.
3. Includes state and local government employees.
4. Based on 340B "parent" facilities, not satellite sites or contract pharmacies.
5. 340B drug purchases at Wholesaler Acquisition Cost (WAC).
6. Percentage of 340B business by state, averaged over drug purchases and claims.